{"anticipatedPostingDate":"2028-10","denomUnitsSelected":"Participants","description":"TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.","reportingStatus":"NOT_POSTED","timeFrame":"96 weeks after last patient first dose","title":"Time to Discontinuation of Study Treatment Due to Adverse Events (TTDAE)","type":"SECONDARY"}